Resectable Pancreatic Cancer: Neoadjuvant or Adjuvant Therapy?

Newsfeed Image, Light Gray Text On Dark Gray Background
For potentially curable treatment of resectable pancreatic cancer, adjuvant therapy remains the standard “for now,” but evidence is growing that neoadjuvant therapy may be more beneficial, at least in certain patient subsets, according to Thomas Seufferlein, MD, PhD, Professor of Medicine at the University of Ulm in Germany.

At the European Society for Medical Oncology (ESMO) 2017 Congress, Dr. Seufferlein described the efficacy of neoadjuvant therapy but acknowledged several questions remain.1 Neoadjuvant therapy will not reach its full potential until these issues are clarified.
Pros and Cons, in Brief. Read more . . .